Researchers at The University of Texas MD Anderson Cancer Center have developed a promising new antibody therapy, known as 77A, which shows potential in enhancing the immune response against various blood and solid cancers. This investigational treatment targets the heat shock protein HSP70, which is often overproduced in tumors, allowing them to evade immune detection. The study results were presented on December 6, 2025, at the 67th American Society of Hematology (ASH) Annual Meeting.
Mechanism of Action and Laboratory Results
Led by Jun Wei, M.D., Ph.D., and Robert Z. Orlowski, M.D., Ph.D., the research highlights how 77A activates T cells and natural killer (NK) cells, which are essential components of the immune system. By targeting HSP70, 77A helps to reshape the tumor environment and supports long-lasting immune responses. In laboratory models, this antibody enhanced the effects of existing treatments, including chemotherapy, radiation, and immunotherapies, across multiple tumor types.
Wei emphasized the significance of the findings, stating, “There is tremendous promise in the way 77A is capable of rewiring the immune system, enabling it to respond effectively against multiple cancers.” This ability to improve the immune response is crucial, particularly for patients who face treatment resistance from traditional therapies.
Next Steps and Future Implications
In addition to its strong laboratory performance, early tests involving human immune cells indicated that 77A could enhance immune responses in healthy donors. These developments suggest that the therapy may pave the way for further clinical trials, potentially establishing it as a versatile new treatment option. Orlowski noted, “These results give us confidence that 77A could become a versatile immunotherapy.”
The research is supported by Blood Cancer United (formerly the Leukemia & Lymphoma Society). The team is now focused on advancing a humanized version of the antibody into clinical trials to evaluate its effectiveness in patients diagnosed with various cancers.
With its innovative approach to activating the immune system, 77A represents a significant advancement in cancer therapy. Further investigations will determine its potential impact on patient treatment outcomes in the ongoing fight against cancer.
